Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

14.5K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
14.5K
Positive Regulator Molecules02:39

Positive Regulator Molecules

5.5K
Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.
5.5K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
Necrosis01:16

Necrosis

4.6K
Necrosis is considered as an “accidental” or unexpected form of cell death that ends in cell lysis. The first noticeable mention of “necrosis” was in 1859 when Rudolf Virchow used this term to describe advanced tissue breakdown in his compilation titled “Cell Pathology”.
Morphological Manifestations of Necrosis
Necrotic cells show different types of morphological appearance depending on the type of tissue and infection. In coagulative necrosis, cells become...
4.6K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

604
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
604
Amyloid Fibrils03:03

Amyloid Fibrils

9.6K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
9.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Deep-level defects and their optoelectronic impact in 2D WSe₂ heterostructures.

Nanotechnology·2026
Same author

Proteomic Changes in Patients with LADA-Type Diabetes: Prospects for Diagnostic Biomarkers.

International journal of molecular sciences·2026
Same author

Scyllo-Inositol as a Neuroactive Agent: From Pharmacokinetics to Neuroprotective and Antiepileptic Effects.

Nutrients·2026
Same author

Potential Anxiolytic Effects of Selected Inositol Stereoisomers-A Narrative Review.

Cells·2026
Same author

Myo-Inositol: Pharmacokinetics, Biological Functions, and Therapeutic Potential in Liver Protection: Insights from Preclinical Models.

Antioxidants (Basel, Switzerland)·2026
Same author

AlInAs step-graded buffer for reducing dark current in InAs based photodetector.

Optics express·2025

Related Experiment Video

Updated: Jul 23, 2025

Author Spotlight: Decoding Mitochondrial Aging
08:48

Author Spotlight: Decoding Mitochondrial Aging

Published on: June 30, 2023

4.0K

Cyclitols: From Basic Understanding to Their Association with Neurodegeneration.

Maria Derkaczew1,2, Piotr Martyniuk1,2, Adam Osowski1

  • 1Department of Human Physiology and Pathophysiology, School of Medicine, Collegium Medicum, University of Warmia and Mazury, 10-082 Olsztyn, Poland.

Nutrients
|July 11, 2023
PubMed
Summary

Myo-inositol (MI) shows promise for treating neurodegenerative disorders like Alzheimer's and Parkinson's. Dietary supplementation with MI may also help alleviate associated depressive symptoms, warranting further research.

Keywords:
Alzheimer’s diseaseHuntington’s diseaseParkinson’s diseased-pinitolinositol phosphatesmyo-inositolneurodegenerative disordersspinocerebellar ataxias

More Related Videos

Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System
09:52

Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System

Published on: December 28, 2017

10.7K
Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

8.0K

Related Experiment Videos

Last Updated: Jul 23, 2025

Author Spotlight: Decoding Mitochondrial Aging
08:48

Author Spotlight: Decoding Mitochondrial Aging

Published on: June 30, 2023

4.0K
Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System
09:52

Modified Roller Tube Method for Precisely Localized and Repetitive Intermittent Imaging During Long-term Culture of Brain Slices in an Enclosed System

Published on: December 28, 2017

10.7K
Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

8.0K

Area of Science:

  • Biochemistry
  • Neuroscience
  • Cell Biology

Background:

  • Myo-inositol (MI) is a common cyclitol crucial for various cellular functions in eukaryotes.
  • MI and its derivatives are involved in signal transduction, membrane biogenesis, and osmoregulation.
  • Neurodegenerative disorders represent a significant unmet medical need.

Purpose of the Study:

  • To evaluate the therapeutic potential of Myo-inositol (MI) for neurodegenerative disorders.
  • To explore MI derivatives and related metabolic interventions for treating these conditions.
  • To review existing literature on MI's role in diseases like Alzheimer's, Parkinson's, Huntington's, and Spinocerebellar ataxias.

Main Methods:

  • Literature review of studies investigating Myo-inositol (MI) and its derivatives.
  • Analysis of research focusing on MI's efficacy in treating neurodegenerative diseases.
  • Examination of MI's impact on cellular processes relevant to neurodegeneration.

Main Results:

  • Myo-inositol (MI) demonstrates a promising effect in the dietary supplementation for treating neurodegenerative disorders.
  • MI may also be beneficial in alleviating depressive symptoms associated with these conditions.
  • Further research is needed to fully elucidate the therapeutic mechanisms and optimize the use of MI and related compounds.

Conclusions:

  • Myo-inositol (MI) presents a potential therapeutic avenue for neurodegenerative diseases.
  • Dietary supplementation with MI offers a promising approach for managing these conditions and associated mood disturbances.
  • Continued investigation into MI metabolism and derivatives is essential for advancing treatment strategies.